← Back to Search

Naloxegol and Opioid-induced Constipation

Phase 2 & 3
Waitlist Available
Led By Scott McCardle, MD
Research Sponsored by TriHealth Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-operative day 5

Summary

This trial is testing whether adding naloxegol to a cardiac surgery pre-operative regimen is effective.

Eligible Conditions
  • Constipation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-operative day 5
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-operative day 5 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time to substantial bowel movement
Secondary study objectives
Rescue medications
Other study objectives
Length of stay

Side effects data

From 2022 Phase 4 trial • 136 Patients • NCT03235739
1%
Troponin elevation and ST elevation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment-Naloxegol
Placebo Arm

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NaloxegolExperimental Treatment1 Intervention
naloxegol 25 mg pill
Group II: PlaceboPlacebo Group1 Intervention
placebo pill
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Naloxegol 25 MG
2017
Completed Phase 4
~140

Find a Location

Who is running the clinical trial?

TriHealth Inc.Lead Sponsor
99 Previous Clinical Trials
53,543 Total Patients Enrolled
2 Trials studying Constipation
169 Patients Enrolled for Constipation
Scott McCardle, MDPrincipal InvestigatorBethesda North TriHealth Hospital
~35 spots leftby Dec 2025